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LETTERS TO THE MJM
Dear MJM,
It was a delightful experience to read the print copy
of the McGill Journal of Medicine. Our previous
experience of your journal was through your website.
We congratulate the student team on producing an
extremely professional journal. The paper and the print
quality are comparable to the best journals in the world.
The 9.2 issue carried a good collection of articles from
various areas of medical science. We especially liked
the Commentary article 'Who do I serve?'. The feature
reviews in the special forum on Reflections by
Neuroscientists were interesting.
Being medical students and clinical pharmacologists
from a developing country, we were especially
interested in the article by Junaid Subhan on ‘’TRIPS
agreement and public health. In Nepal, the domestic
pharmaceutical industry is rapidly developing and some
manufacturers have obtained the WHO Good
Manufacturing Practice (GMP) certification. However,
domestic manufacturers meet only about 50% of the
country's requirements and the rest is met by imports
from India, Bangladesh and China. India became TRIPS
compliant in 2005 and Nepal yet has few years to do so.
The author has given a very lucid elucidation of WTO
and TRIPS. A major drug manufacturer in South Asia
and the world is India. As Indian medicines are
imported into Nepal, India also influences the Nepalese
market. Before 2005, India did not allow molecules to
be patented and only allowed process patents.
Molecules introduced into the Indian market by one
company could be manufactured by another company
using a different process without infringing on the
patent. This kept drug prices low and medicines were
affordable to the vast majority. A downside, however,
was that innovator companies were reluctant to
introduce new molecules into the Indian market.
Post 2005, new molecules are introduced faster into
the Indian market and many Indian multinationals are
investing heavily on research and development of new
molecules. Compulsory licensing, as suggested by the
author, may help in making essential medicines
available at a low cost in the developing world. Parallel
importing is also another good strategy to ensure access.
India, China and Brazil are the major generic
manufacturers that have provided cheap antiretrovirals
and anti-TB drugs to other developing and even  to
developed countries.
We basically agree with the author that the term
'essential medicines' should be defined within TRIPS.
The change in the definition of essential medicines may
be a good strategy. However, as rightly said by the
author, companies may concentrate more on drugs
which are strongly protected by patents and on which
they will get a greater return on investment. This has
already happened and tropical diseases and diseases of
the developing world were neglected. Recently a
number of initiatives like Medicines for Malaria
Venture (MMV), the Drugs for Neglected Disease
Institutive (DNDi) and the Global Alliance for TB Drug
Development (based on public-private partnerships)
have been started to encourage research and
development of medicines for diseases of developing
countries. Looking at the history of product patents in
India, a long product patent may not by itself be an
incentive for an innovator company to concentrate on
developing a product. This had happened with
molecules like ciprofloxacin and roxithromycin. Indian
companies had also created copies of Sildenafil citrate.    
Restricting process patents only to essential medicines
may be a good idea in principle. Again however, the
Indian example tells us that the innovator company may
enjoy protection only for a very short period of time. We
personally think it is much more difficult to develop and
test a new molecule while is is much easier to
manufacture an already introduced molecule using a
different technique. Placing restrictions on the second
developer may be a good idea in principle. However,
the practical details will require a lot of work. 
We congratulate the author on a well-written article
and for exploring a possible means of balancing the
interests of the innovator companies and the public
health needs of developing countries. This is an area of
debate. Medical students and doctors, we believe,
should have at least a broad idea about TRIPS, patent
protection, and its likely effects on the cost and
availability of medicines.
Sincerely,
Bishnu R Giri, eighth semester medical student
Manipal College of Medical Sciences, Nepal
P.Ravi Shankar,  MD, Department of Pharmacology
Manipal College of Medical Sciences, Nepal
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